New insights into the physiology of bone regulation: The role of neurohormones

Physiological Research

Volumn 63, Issue 4, 2014, Pages 421-427

  Zofkova I ^a   Matucha, P ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Adrenocorticotropin; Beta adrenergic system; Bone remodeling; Cannabinoids; Melatonin; Oxytocin; Serotonin; Thyrotropin

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANIMAL; BONE; BONE DEVELOPMENT; BONE REMODELING; FEMALE; HUMAN; MALE; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; FEMALE; HUMANS; MALE; NEUROTRANSMITTER AGENTS; OSTEOGENESIS;

EID: 84910024168     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. ARAI M, NAGASAWA T, KOSHIHARA Y, YAMAMOTO S, TAGARI A: Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta 1640: 137-142, 2003.
2. BAB I, ZIMMER A, MELAMED E: Cannabinoids and the skeleton: from mariujana to reversal of bone loss. Ann Med 41: 560-567, 2009.
3. BONNET N, PIERROZ DD, FERRARI SL: Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J Musculoskelet Neuronal Interact 8: 94-104, 2008.
4. BREUIL V, AMRI EZ, PANAIA-FERRARI P, TESTA J, ELABD C, ALBERT-SABOUNADIERE C, ROUX CH, AILHAUD G, DANI C, CARLE GF, EULLER-ZIEGLER L: Oxytocin and bone remodelling: Relationships with neuropituitary hormones, bone status and body composition. Point Bone Spin 78: 611-615, 2011.
5. CANNON JG, CORTEZ-COOPER M, MEADERS E, STALLINGS J, HADDOW S, KRAJ B, SLOAN G, MULLOY A: Follicle-stimulating hormone, interleukin-1, and bone density in adult women. Am J Physiol Regul Integr Comp Physiol 298: R790-R798, 2010.
6. CHEN F, HAHN TJ, WEINTRAUB NT: Do SSRIs play a role in decreasing bone mineral density? J Am Med Dir Assoc 13: 413-417, 2012.
7. COLAIANNI G, SUN L, DI BENEDETTO A, TAMMA R, ZHU LL, CAO J, GRANO M, YUEN T, COLUCCI S, CUSCITO C, MANCINI L, LI J, NISHIMORI K, BAB I, LEE HD, IQBAL J, YOUNG WS 3RD, ROSEN C, ZALLONE A, ZAIDI M: Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem 287: 29159-29167, 2012.
8. CORTURIER J, SY A, JOHNSON N, FINDLAY S: Bone mineral density in adolescents with eating disorders exposed to selective serotonin reuptake inhibitors. Eat Disord 21: 238-248, 2013.
9. DE VRIES F, POUWELS S, BRADLE M, LEUFKENS HG, COOPER C, LAMMERS JW, VAN STAA TP: Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 16: 612-619, 2007.
10. DIEM SJ, BLACKWELL TL, STONE KL, YAFFE K, HANEY EM, BLIZIOTES MM, ENSRUD KE: Use of antidepresants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167: 1240-1245, 2007.
11. DRIESSLER F, BALDOCK PA: Hypothalamic regulation of bone. J Mol Endocrinol 45: 175-181, 2010.
12. ELEFTERIOU F, AHN JD, TAKEDA S, STARBUCK M, YANG X, LIU X, KONDO H, RICHARDS WG, BANNOU TW, NODA M, CLEMENT K, VAISSE C, KARSENTY G: Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520, 2005.
13. ELEFTERIOU F, CAMPBELL P, MA Y: Control of bone remodeling by the peripheral sympathetic nervous system. Calcif Tissue Int 94: 140-151, 2014.
14. FARR JN, CHARKOUDIAN N, BARNES JN, MONROE DG, MCCREADY LK, ATKINSON EJ, AMIN S, MELTON LJ 3RD, JOYNER MJ, KHOLA S: Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. J Clin Endocrinol Metab 97: 4219-4227, 2012.
15. FRANGUINHO F, LIZ MA, NUNES AF, NETO E, LAMGHARI M, SOUSA MM: Neuropeptide Y and osteoblast differentiation-the balance between the neuro-osteogenic network and local control. FEBS J 277: 3664-3667, 2010.
16. GORDELADZE JO, RESELAND JE: A unified model for the action of leptin on bone turnover. J Cell Biochem 88: 706-712, 2003.
17. GRADOSOVA I, ZIVNA H, ZIVNY P: Influence of metoprolol on bone metabolism in male Wistar rats after oophorectomy (in Czech). Osteological Bulletin 16: 132-136, 2011.
18. HAMRICK MW, FERRARI SL: Leptin and the sympathetic connection of fat to bone. Osteoporosis Int 19: 905-912, 2008.
19. IDRIS AI, RALSTON SH: Cannabinoids and bone: friend or foe? Calcif Tissue Int 87: 285-297, 2010.
20. IDRIS AI, RALSTON SH: Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne) 3: 136, 2012.
21. IMAM A, IQBAR J, BLAIR HC: Role of the pituitary-bone axis in skeletal pathophysiology. Opin Endocrinol Diabetes Obes 16: 423-429, 2009.
22. ISALES CM, ZAIDI M, BLAIR HC: ACTH is a novel regulator of bone mass. Ann NY Acad Sci 1192: 110-116, 2010.
23. KARSENTY G, YADAV VK: Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med 62: 323-331, 2011.
24. KAWAI M, ROSEN CJ: Minireview: A skeleton in serotonin's closet? Endocrinology 151: 4103-4108. 2010.
25. KHOR EC, BALDOCK P: The NPY system and its neural and neuroendocrine regulation of bone. Curr Osteoporos Rep 10: 160-168, 2010.
26. KODE A, MOSIALOU I, SILVA BC, RACHED MT, ZHOU B, WANG J, TOWNES TM, HEN R, DEPINHO RA, GUO XE, KOUSTENI S: FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J Clin Invest 122: 3490-3503, 2012.
27. KONDO A, TOVARU A: In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab 285: E661-E667, 2003.
28. KOYAMA H, NAKADE O, TAKADA Y, KAKU T, LAU KH: Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoklast formationand activation. J Bone Miner Res 17: 1219-1229, 2002.
29. KRISTENSEN P, JUDGE ME, THIM L, RIBEL U, CHRISTJANSEN KN, WULFF BS, CLAUSEN JT, JENSEN PB, MADSEN OD, VRANG N, LARSEN PJ, HASTRUP S: Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72-76, 1998.
30. LAWSON EA, ACKERMAN KE, ESTELLA NM, GUERECA G, PIERCE L, SLUSS PM, BOUXEIN ML, KLIBANSKI A, MISRA M: Nocturnal oxytocin secretion is lower in amenorrheic athletes than nonathletes and associated with bone microarchitecture and finite element analysis parameters. Eur J Endocrinol 168: 457-464, 2013.
31. LAWSON EA, DONOHO DA, BLUM JI, MANAGHAN EM, MISRA M, HERZOG DB, SLUSS PM, MILLER KK, KLIBANSKI A: Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. J Clin Psychiatry 72: 1546-1551, 2011.
32. LEE NJ, NGUYEN AD, ENRIQUEZ RE, DOVLE KL, SAINSBURY A, BLADOCK PA, HERZOG H: Osteoblast specific Y1 receptor deletion enhances bone mass. Bone 48: 461-467, 2011.
33. MA R, MORSHED S, LATIF R, ZAIDI M, DAVIES TF: The influence of thyroid-stimulating hormone and thyroidstimulating hormone receptor antibodies on osteoclastogenesis. Thyroid 21: 897-906, 2011.
34. MASI L: Crosstalk between the brain and bone. Clin Cases Bone Metab 9: 13-16, 2012.
35. MATIC I, MATTHEWS BG, KIZIVAT T, IQWE JC, MARIJANOVIC I, RUOHONEN ST, SAVONTAUS E, ADAMS DJ, KALAJZIC I: Bone-specific overexpression of NPY modulates osteogenesis. J Musculoskelet Neuronal Interact 12: 209-218, 2012.
36. MINKOWITZ B, BOSKEY AL, LANE JM, PEARLMAN HS, VIGORITA VJ: Effects or propranolol on bone metabolism in the rat. J Orthop Res 9: 869-875, 1991.
37. MOTYL KJ, ROSEN CJ: Understanding leptin-dependent regulation of skeletal homeostasis. Biochemie 94: 2089-2096, 2012.
38. PASCO JA, HENRY MJ, SANDERS KM, KOTOWICZ MA, SEEMAN E, NICHOLSON GC: Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19: 19-24, 2004.
39. SAMPATH TK, SIMIC P, SENDAK R, DRACA N, BOWE AE, O'BRIEN S, SCHIAVI SC, MCPHERSON JM, VUKICEVIC S: Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 22: 849-859, 2007.
40. SANSONE RA, SANSONE LA: SSRIs: bad to the bone? Innov Clin Neurosci 9: 42-47, 2012.
41. SATO S, HANADA R, KIMURA A, ABE T, MATSUMOTO T, IWASAKI M, INOSE H, IDA T, MIEDA M, TAKEUCHI Y, FUKUMOTO S, FUJITA T, KATO S, KANGAWA K, KOJIMA M, SHINOMIYA K, TAKEDA S: Central control of bone remodeling by neuromedin U. Nat Med 13: 1234-1240, 2007.
42. SCHLIENGER RG, KRAENZIN ME, JICH SS, MEIER CR: Use of beta-blocker and risk of fractures. JAMA 292: 1326-1332, 2004.
43. SENDAK RA, SAMPATH K, MCPHERSON JM: Newly reported roles of thyroid-stimulating hormone and folliclestimulating hormone in bone remodelling. Int Orthop 31: 753-757, 2007.
44. SHI YC, BALDOCK PA: Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone 50: 430-436, 2012.
45. SHI YC, LIN S, WONG IP, BALDOCK PA, ALJANOVA A, ENRIGUEZ RF, CASTILLO L, MITCHELL NF, YE JM, ZHANG L, MACIA L, YULVANINGSIH E, NGUYEN AD, RIEPLER SJ, HERZOG H, SAINSBURY A: NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One 5: e11361, 2010.
46. SOUSA DM, MCDONALD MM, MIKULEC K, PEACOCK, HERZOG H, LAMGHARI M, LITTLE DG, BALDOCK PA: Neuropeptide Y modulates fracture healing through Y1 receptor signaling. J Orthop Res 31: 1570-1578, 2013.
47. SUGITANI I, FUJIMOTO Y: Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 150: 1250-1257, 2011.
48. TAKEUCHI Y: Possible involvement of pituitary hormones in bone metabolism. Clin Calcium 23: 195-205, 2013.
49. VERDEL BM, SOUVEREIN PC, EGBERTS TC, VAN STAA TP, LEUFKENS HG, DE VRIES F: Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47: 604-609, 2010.
50. WHYTE LS, FORD L, RIDGE SA, CAMERON GA, ROGERS MJ, ROSS RA: Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol 165: 2584-2597, 2012.
51. WONG IP, NGUEN AD, KHOR EC, ENRIGUEZ RF, EISMAN JA, SAINSBURY A, HERZOG H, BALDOCK PA: Neuropeptide Y is a critical modulator of leptin's regulation of cortical bone. J Bone Miner Res 28: 886-898, 2013.
52. YADAV VK, DUCY P: Lrp5 and bone formation: a serotonin-dependent pathway. Ann NY Acad Sci 1192: 103-109, 2010.
53. ZOFKOVA I, HILL M: Biochemical markers of bone remodeling correlate negatively with circulating TSH in postmenopausal women. Endocr Regul 42: 121-127, 2008.